Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines

H. Masuda, R. F. Ozols, G. M. Lai, A. Fojo, M. Rothenberg, T. C. Hamilton

Research output: Contribution to journalArticle

294 Citations (Scopus)

Abstract

A human ovarian cancer cell line, A2780, derived from an untreated ovarian cancer patient and relatively sensitive to cisplatin was treated by stepwise incubation with cisplatin to produce a cisplatin-resistant variant, 2780(CP). The relative abilities of these cell lines to repair cisplatin-induced damage to cellular DNA then was examined by measure of [ 3H]thymidine incorporation into normal density DNA separated from bromodeoxyuridine-substituted DNA on alkaline cesium chloride gradients. These studies revealed that primary cisplatin resistance present in 2780(CP) was associated with a near twofold-increased ability to repair damage induced by the drug under conditions where 2780(CP) was approximately 5-fold resistant to cisplatin. Aphidicolin, a specific inhibitor of DNA polymerase α, showed a dose-dependent capacity to inhibit DNA repair in this system with maximum inhibition of 63% at 4 μg/ml. It was also found that inhibition of DNA repair during and shortly after cisplatin exposure resulted in an approximately threefold increase in the cytotoxicity of cisplatin as monitored by clonogenic cell survival in the resistant but not the sensitive parental cell line.

Original languageEnglish
Pages (from-to)5713-5716
Number of pages4
JournalCancer Research
Volume48
Issue number20
Publication statusPublished - 1988
Externally publishedYes

Fingerprint

DNA Repair
Ovarian Neoplasms
Cisplatin
Cell Line
DNA
Aphidicolin
Nucleic Acid Synthesis Inhibitors
Bromodeoxyuridine
Thymidine
Cell Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. / Masuda, H.; Ozols, R. F.; Lai, G. M.; Fojo, A.; Rothenberg, M.; Hamilton, T. C.

In: Cancer Research, Vol. 48, No. 20, 1988, p. 5713-5716.

Research output: Contribution to journalArticle

Masuda, H, Ozols, RF, Lai, GM, Fojo, A, Rothenberg, M & Hamilton, TC 1988, 'Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines', Cancer Research, vol. 48, no. 20, pp. 5713-5716.
Masuda, H. ; Ozols, R. F. ; Lai, G. M. ; Fojo, A. ; Rothenberg, M. ; Hamilton, T. C. / Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. In: Cancer Research. 1988 ; Vol. 48, No. 20. pp. 5713-5716.
@article{3f6db2c9d7764559bbc831d7e8c12aca,
title = "Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines",
abstract = "A human ovarian cancer cell line, A2780, derived from an untreated ovarian cancer patient and relatively sensitive to cisplatin was treated by stepwise incubation with cisplatin to produce a cisplatin-resistant variant, 2780(CP). The relative abilities of these cell lines to repair cisplatin-induced damage to cellular DNA then was examined by measure of [ 3H]thymidine incorporation into normal density DNA separated from bromodeoxyuridine-substituted DNA on alkaline cesium chloride gradients. These studies revealed that primary cisplatin resistance present in 2780(CP) was associated with a near twofold-increased ability to repair damage induced by the drug under conditions where 2780(CP) was approximately 5-fold resistant to cisplatin. Aphidicolin, a specific inhibitor of DNA polymerase α, showed a dose-dependent capacity to inhibit DNA repair in this system with maximum inhibition of 63{\%} at 4 μg/ml. It was also found that inhibition of DNA repair during and shortly after cisplatin exposure resulted in an approximately threefold increase in the cytotoxicity of cisplatin as monitored by clonogenic cell survival in the resistant but not the sensitive parental cell line.",
author = "H. Masuda and Ozols, {R. F.} and Lai, {G. M.} and A. Fojo and M. Rothenberg and Hamilton, {T. C.}",
year = "1988",
language = "English",
volume = "48",
pages = "5713--5716",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines

AU - Masuda, H.

AU - Ozols, R. F.

AU - Lai, G. M.

AU - Fojo, A.

AU - Rothenberg, M.

AU - Hamilton, T. C.

PY - 1988

Y1 - 1988

N2 - A human ovarian cancer cell line, A2780, derived from an untreated ovarian cancer patient and relatively sensitive to cisplatin was treated by stepwise incubation with cisplatin to produce a cisplatin-resistant variant, 2780(CP). The relative abilities of these cell lines to repair cisplatin-induced damage to cellular DNA then was examined by measure of [ 3H]thymidine incorporation into normal density DNA separated from bromodeoxyuridine-substituted DNA on alkaline cesium chloride gradients. These studies revealed that primary cisplatin resistance present in 2780(CP) was associated with a near twofold-increased ability to repair damage induced by the drug under conditions where 2780(CP) was approximately 5-fold resistant to cisplatin. Aphidicolin, a specific inhibitor of DNA polymerase α, showed a dose-dependent capacity to inhibit DNA repair in this system with maximum inhibition of 63% at 4 μg/ml. It was also found that inhibition of DNA repair during and shortly after cisplatin exposure resulted in an approximately threefold increase in the cytotoxicity of cisplatin as monitored by clonogenic cell survival in the resistant but not the sensitive parental cell line.

AB - A human ovarian cancer cell line, A2780, derived from an untreated ovarian cancer patient and relatively sensitive to cisplatin was treated by stepwise incubation with cisplatin to produce a cisplatin-resistant variant, 2780(CP). The relative abilities of these cell lines to repair cisplatin-induced damage to cellular DNA then was examined by measure of [ 3H]thymidine incorporation into normal density DNA separated from bromodeoxyuridine-substituted DNA on alkaline cesium chloride gradients. These studies revealed that primary cisplatin resistance present in 2780(CP) was associated with a near twofold-increased ability to repair damage induced by the drug under conditions where 2780(CP) was approximately 5-fold resistant to cisplatin. Aphidicolin, a specific inhibitor of DNA polymerase α, showed a dose-dependent capacity to inhibit DNA repair in this system with maximum inhibition of 63% at 4 μg/ml. It was also found that inhibition of DNA repair during and shortly after cisplatin exposure resulted in an approximately threefold increase in the cytotoxicity of cisplatin as monitored by clonogenic cell survival in the resistant but not the sensitive parental cell line.

UR - http://www.scopus.com/inward/record.url?scp=0023750017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023750017&partnerID=8YFLogxK

M3 - Article

C2 - 3139281

AN - SCOPUS:0023750017

VL - 48

SP - 5713

EP - 5716

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 20

ER -